Printer Friendly

QUIDEL APPOINTS DR. MARY LAKE POLAN TO BOARD OF DIRECTORS

 SAN DIEGO, Feb. 9 /PRNewswire/ -- QUIDEL Corp. (NASDAQ: QDEL) today announced the appointment of Dr. Mary Lake Polan to its board of directors. Polan presently serves as chairman, Department of Gynecology and Obstetrics at Stanford University School of Medicine.
 Polan, a leader in fertility/infertility and women's health issues, has more than 18 years experience in the field of obstetrics and gynecology. Polan received her Ph.D. from Yale University in 1970 and her M.D. from Yale University School of Medicine in 1975 and in 1984 was certified by the American Board of Obstetrics and Gynecology in reproductive endocrinology. Polan is the author of 63 original research publications, 15 book chapters and five books involving reproductive medicine and infertility. Over the years, she has received numerous academic appointments leading to her present position as chairman, Department of Gynecology and Obstetrics at Stanford University School of Medicine.
 "We are pleased to have an individual of Dr. Polan's caliber join our board," said Scott L. Glenn, chairman and chief executive officer of QUIDEL. "Dr. Polan is both a pioneer and a champion in the area of women's health care research and has been instrumental in increasing research funding in the area of women's health. We look forward to her support and expertise while our company develops novel diagnostic tests for family planning and women's health care."
 QUIDEL Corp. develops, manufactures and markets rapid immunodiagnostic products that provide simple, accurate and cost- effective diagnoses in the areas of human fertility, infectious diseases, allergy and autoimmune disorders. These tests are designed for use in the physician's office, clinical laboratory and home testing markets.
 -0- 2/9/93
 /CONTACT: Scott L. Glenn, chairman and CEO, 619-552-7900, or Mark Francois, manager, investor relations, 619-552-7931, both of QUIDEL/
 (QDEL)


CO: QUIDEL Corp. ST: California IN: MTC SU: PER

KJ-JB -- SD002 -- 4448 02/09/93 08:06 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 9, 1993
Words:311
Previous Article:PYXIS ANNOUNCES ADDITIONAL GROUP AGREEMENTS
Next Article:DH TECHNOLOGY ANNOUNCES EARNINGS
Topics:


Related Articles
ULCER CURE LINKED TO COMMON BACTERIUM; ULCER PATIENTS SHOULD INQUIRE ABOUT TEST FOR H. PYLORI
QUIDEL FORMS JOINT DISTRIBUTION VENTURE IN EUROPE
ULCER CURE LINKED TO TREATMENT OF COMMON BACTERIUM -- KEY TOPIC AT NATIONAL DIGESTIVE DISEASE WEEK
QUIDEL EXPANDS EUROPEAN DISTRIBUTION; SIGNS PRODUCT LICENSING AGREEMENT FOR POLISH MARKET
QUIDEL AND BECTON DICKINSON SIGN NEW AGREEMENT - QUIDEL ACQUIRES RIGHTS TO CONSUMER FERTILITY PRODUCTS
QUIDEL STRENGTHENS MANAGEMENT TEAM WITH APPOINTMENT OF ELLIOT WERBER AS VICE PRESIDENT, SALES AND MARKETING
QUIDEL Board Elects Andre de Bruin To Its Board Of Directors And Has Appointed Him Vice Chairman
Quidel Strengthens Management Team With Appointment of Glenn Holmes As Vice President, Sales and Marketing
Response Biomedical appoints S. Wayne Kay Chief Executive Officer.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters